Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study

Journal of the American College of Cardiology

Volumn 67, Issue 12, 2016, Pages 1444-1455

  Teerlink, John R ^a,b   Felker, G Michael ^c   McMurray, John J V ^d   Ponikowski, Piotr ^e   Metra, Marco ^f   Filippatos, Gerasimos S ^g   Ezekowitz, Justin A ^h   Dickstein, Kenneth ^i,j   Cleland, John G F ^k   Kim, Jae B ^l   Lei, Lei ^l   Knusel, Beat ^l   Wolff, Andrew A ^m   Malik, Fady I ^m   Wasserman, Scott M ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f UNIVERSITY OF BRESCIA   (Italy)

^g NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ UNIVERSITY OF BERGEN   (Norway)

^j STAVANGER UNIVERSITY HOSPITAL   (Norway)

^k ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^l AMGEN INC   (United States)

^m Cytokinetics Inc   (United States)

more..

Author keywords

arrhythmia; cardiac myosin activator; dyspnea; inotrope

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; MINERALOCORTICOID ANTAGONIST; OMECAMTIV MECARBIL; PLACEBO; TROPONIN; UREA;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; AGED; ARTICLE; ATRIAL FIBRILLATION; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOKALEMIA; HYPOTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUDDEN CARDIAC DEATH; SUPRAVENTRICULAR TACHYCARDIA; UNSPECIFIED SIDE EFFECT; ACUTE DISEASE; ADOLESCENT; ADULT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; ECHOCARDIOGRAPHY; ECHOGRAPHY; FOLLOW UP; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART VENTRICLES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; PROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME; TROPONIN; UREA; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84962318547     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.01.031     Document Type: Article

References (29)

1. G.M. Felker, P.S. Pang, K.F. Adams, and et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward Circ Heart Fail 3 2010 314 325
2. G. Hasenfuss, and J.R. Teerlink Cardiac inotropes: current agents and future directions Eur Heart J 32 2011 1838 1845
3. J.J. McMurray, S. Adamopoulos, S.D. Anker, and et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 Eur Heart J 33 2012 1787 1847
4. C.W. Yancy, M. Jessup, B. Bozkurt, and et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 e147 e239
5. F.I. Malik, J.J. Hartman, K.A. Elias, and et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure Science 331 2011 1439 1443
6. Y.T. Shen, F.I. Malik, X. Zhao, and et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure Circ Heart Fail 3 2010 522 527
7. J.R. Teerlink, C.P. Clarke, K.G. Saikali, and et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study Lancet 378 2011 667 675
8. J.G. Cleland, J.R. Teerlink, R. Senior, and et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial Lancet 378 2011 676 683
9. L.K. Newby, R.L. Jesse, J.D. Babb, and et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents J Am Coll Cardiol 60 2012 2427 2463
10. J.R. Teerlink, M. Metra, G.M. Felker, and et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study Lancet 373 2009 1429 1439
11. J. Hsu Multiple Comparisons: Theory and Methods 1996 Chapman & Hall London, United Kingdom
12. D.G. Kramer, T.A. Trikalinos, D.M. Kent, and et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach J Am Coll Cardiol 56 2010 392 406
13. A.M. Weissler, W.S. Harris, and C.D. Schoenfeld Systolic time intervals in heart failure in man Circulation 37 1968 149 159
14. R.L. West, A.F. Hernandez, C.M. O'Connor, and et al. A review of dyspnea in acute heart failure syndromes Am Heart J 160 2010 209 214
15. C.M. O'Connor, R.C. Starling, A.F. Hernandez, and et al. Effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 2011 32 43
16. J.R. Teerlink, G. Cotter, B.A. Davison, and et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial Lancet 381 2013 29 39
17. J.L. Januzzi Jr., G. Filippatos, M. Nieminen, and M. Gheorghiade Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section Eur Heart J 33 2012 2265 2271
18. M. Metra, L. Bettari, F. Pagani, and et al. Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation Clin Res Cardiol 101 2012 663 672
19. M. Metra, G. Cotter, B.A. Davison, and et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes J Am Coll Cardiol 61 2013 196 206
20. C.M. O'Connor, M. Fiuzat, C. Lombardi, and et al. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study Circ Heart Fail 4 2011 724 732
21. G.M. Felker, V. Hasselblad, W.H. Tang, and et al. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study Eur J Heart Fail 14 2012 1257 1264
22. Y. Liu, H.D. White, B. Belknap, and et al. Omecamtiv mecarbil modulates the kinetic and motile properties of porcine beta-cardiac myosin Biochemistry 54 2015 1963 1975
23. J.P. Bakkehaug, A.B. Kildal, E.T. Engstad, and et al. Myosin activator omecamtiv mecarbil increases myocardial oxygen consumption and impairs cardiac efficiency mediated by resting myosin ATPase activity Circ Heart Fail 8 2015 766 775
24. J.R. Teerlink, F.I. Malik, and D.A. Kass Letter by Teerlink et al Regarding article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity." Circ Heart Fail 8 2015 1141
25. M.S. Cuffe, R.M. Califf, K.F. Adams Jr., and et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial JAMA 287 2002 1541 1547
26. M. Packer, W.S. Colucci, L. Fisher, and et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure J Am Coll Cardiol HF 1 2013 103 111
27. G. Cotter, M. Metra, B.D. Weatherley, and et al. Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure - association with signs and symptoms, hospitalization duration, and 60-day outcomes Cardiology 115 2010 29 36
28. J.P. Kelly, R.J. Mentz, V. Hasselblad, and et al. Worsening heart failure during hospitalization for acute heart failure: insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Am Heart J 170 2015 298 305
29. J. Butler, M. Gheorghiade, A. Kelkar, and et al. In-hospital worsening heart failure Eur J Heart Fail 17 2015 1104 1113